Enter your login e-mail to the account
Search
- The role of fibrates in a statin world
MUDr. Ľubomíra Fábryová, PhD.
(11/2009, Topic of the year ) - Evolokumab pro léčbu familiární hypercholesterolémie
prof. MUDr. Vladimír Bláha, CSc.
(4/2018, Drugs & drug classes ) - Komentár k odporúčaniam ACC/AHA (ACC/AHA Guidelines on the Treatment of Blood Cholesterol)
MUDr. Ľubomíra Fábryová, PhD., prof. MUDr. Andrej Dukát, CSc., FESC
(2/2014, Information & comments ) - Future of hypolipidemic therapy
MUDr. Fábryová Ľubomíra, PhD.
(5/2010, Topic of the year ) - Combined hypolipidemic therapy in current clinical practice
MUDr. Ľubomíra Fábryová, PhD.
(6/2014, Review articles ) - Reach target LDL cholesterol more effective dose of atorvastatin 30 mg in the practice of general practitioners
MUDr. Martin Čaprnda, PhD., MUDr. Ján Hencel, MSc., Mgr. Ján Farkašovský, PharmDr. Silvia Encingerová, Mgr. Oliver Tlčimuka
(5/2015, Original articles & case reports ) - The imperative need to change the routine approach in the management of the patient with arterial hypertension and dyslipidemia. Image of a realistic practice – DISCOVERY study
MUDr. Adriana Šimková, PhD. , MUDr. Anna Vachulová, PhD.,
(3/2024, Original articles & case reports ) - Hypolipidemic treatment of patients with nonalcoholic fatty liver disease
doc. MUDr. Peter Jarčuška, PhD., MUDr. Martin Janičko, MUDr. Eduard Veseliny, MUDr. Ján Fedačko, MUDr. Božena Nováková, prof. MUDr. Daniel Pella, CSc.
(6/2010, Topic of the year ) - Significance of combined hypolipidemic therapy for patients with metabolic syndrome
MUDr. Renáta Palmajová
(3/2010, Original articles & case reports ) - Hypolipidemic treatment and target values of lipids
MUDr. Ondřej Kyselák, prof. MUDr. Vladimír Soška, CSc.
(1/2019, Review articles ) - IMMUNOMODULATORY EFFECTS OF STATINS
doc. MUDr. František Gazdík, PhD.
(5/2007, clearly ) - MANAGING DYSLIPIDAEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE
MUDr. Ľubomíra Fábryová
(10/2005, Topic ) - Role of niacin in a hypolipidaemic treatment in high cardiovascular risk patients
prof. MUDr. Andrej Dukát, CSc., doc. MUDr. Ľudovít Gašpar, CSc., MUDr. Peter Minárik, doc. MUDr. Martin Wawruch, PhD., doc. MUDr. Stanislav Oravec, CSc., MUDr. Peter Sabaka
(1/2010, Topic of the year ) - Combined hypolipidemic therapy using statins and fibrates reducing the cardiovascular risk in the patients with atherogenic dyslipidemia
prof. MUDr. Vladimír Bláha, CSc.
(4/2010, Topic of the year ) - New options in diagnostics and treatment of familial hypercholesterolemia
MUDr. Šárka Tesařová, Prof. MUDr. Michal Vrablík, Ph.D.
(3/2019, Review articles )
- Active substances in medicinal mushrooms
MUDr. Jana Mrázová
(3/2016, Phytotherapy ) - Recent advances in research of Silymarin and its components
Mgr. Jan Soukop, prof. MUDr. Rostislav Večeřa, Ph.D.
(4/2023, Current pharmacotherapy ) - What can statins do in the management of cardiovascular deseases?
MUDr. Marta Filková, prof. MUDr. Ján Murín, CSc.,, MUDr. Miroslav Pernický
(1/2013, Current pharmacotherapy ) - Niacin-laropiprant combination: novel approach not only to treatment of dyslipidemia Complex management of dyslipidemia provides a chance of further reduction of atherosclerotic vascular
MUDr. Michal Vrablík, Ph.D., MUDr. Eva Motyková, prof. MUDr. Richard Češka, CSc.
(1/2011, New medicinal substances )
- A fixed combination Cyclo 3 Fort in the treatment of CVI
MUDr. Jiří Slíva, Ph.D.
(2/2016, Drugs & drug classes )












